Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR−/− and ApoE−/− mice

This publication has 33 references indexed in Scilit:

• Another Step Forward in Refining Risk Stratification
  JACC, 2011
• Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention?
  International Journal of Inflammation, 2011
• Oxidized Low-Density Lipoprotein and Atherosclerosis
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
• Adiponectin Reduces Plasma Triglyceride by Increasing VLDL Triglyceride Catabolism
  Diabetes, 2008
• Disodium Disuccinate Astaxanthin Prevents Carotid Artery Rethrombosis and ex vivo Platelet Activation
  Pharmacology, 2008
• Astaxanthin: A Novel Potential Treatment for Oxidative Stress and Inflammation in Cardiovascular Disease
  The American Journal of Cardiology, 2008
• Natural Products as a Robust Source of New Drugs and Drug Leads: Past Successes and Present Day Issues
  The American Journal of Cardiology, 2008
• Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp
  Life Sciences, 2007
• LDL Apheresis Reduces the Susceptibility of LDL to in Vitro oxidation in a Diabetic Patient With Hemodialysis Treatment
  Diabetes Care, 1996
• Effect of the Antioxidant N,N′ -Diphenyl 1,4-Phenylenediamine (DPPD) on Atherosclerosis in ApoE-Deficient Mice
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995